<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668001</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003611</org_study_id>
    <nct_id>NCT04668001</nct_id>
  </id_info>
  <brief_title>Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome</brief_title>
  <acronym>TransPhoM-DS</acronym>
  <official_title>Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to better understand the effects of transcranial photobiomodulation&#xD;
      (tPBM) on neural oscillations of individuals diagnosed with down syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the effect of tPBM to sham tPBM on gamma neural oscillations in the&#xD;
      brain as assessed by EEG, and on language, attention and memory as assessed by&#xD;
      neuropsychological testing. Participants will be randomized to either tPBM with near-infrared&#xD;
      light (tPBM-NIR) or tPBM-Sham and will undergo 18 treatments (3 treatments per week for 6&#xD;
      weeks) in addition to baseline, short-term and long- term follow up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EEG</measure>
    <time_frame>Baseline to Post-Treatment (~6 weeks)</time_frame>
    <description>Gamma Power (40 Hz) of EEG Signal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Wordless Picture Book/Probes Driven Discussion</measure>
    <time_frame>Baseline to Post-Treatment (~6 weeks)</time_frame>
    <description>Standardized narrative sampling tasks that measure intelligibility, vocabulary, syntax and grammar of language</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cambridge Neuropsychological Test Automated Battery</measure>
    <time_frame>Baseline to Post-Treatment (~6 weeks)</time_frame>
    <description>Reaction Time, Paired Associative Learning, and Motor Screening Task subtests</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Transcranial Photobiomodulation (tPBM-Sham)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Near-Infrared Transcranial Photobiomodulation</intervention_name>
    <description>tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.</description>
    <arm_group_label>Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)</arm_group_label>
    <other_name>tPBM-NIR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Transcranial Photobiomodulation</intervention_name>
    <description>tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain</description>
    <arm_group_label>Sham Transcranial Photobiomodulation (tPBM-Sham)</arm_group_label>
    <other_name>tPBM-Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for this study include:&#xD;
&#xD;
          1. adult men and women between the ages of 18 and 30&#xD;
&#xD;
          2. diagnosis of DS (i.e., clinical diagnosis of Trisomy 21 or Complete Unbalanced&#xD;
             Translocation of Chromosome 21)&#xD;
&#xD;
        Exclusion criteria for this study include:&#xD;
&#xD;
          1. diagnosis of seizure disorder&#xD;
&#xD;
          2. diagnosis of dementia&#xD;
&#xD;
          3. inability to complete study procedures&#xD;
&#xD;
          4. English as a second language&#xD;
&#xD;
          5. speech as the secondary mode of communication&#xD;
&#xD;
          6. speech of less than two-word utterances&#xD;
&#xD;
          7. speech/language therapy two weeks prior to baseline testing and throughout study&#xD;
             completion&#xD;
&#xD;
          8. changes in medications, augmentative devices and other intervention two weeks prior to&#xD;
             baseline testing and throughout study completion&#xD;
&#xD;
          9. untreated obstructive sleep apnea (OSA)&#xD;
&#xD;
         10. contraindications to MRI&#xD;
&#xD;
         11. Participation in other clinical research trials that may influence affect primary&#xD;
             outcomes or adherence to the proposed study, as assessed by the PI and the Co-Is&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Cassano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Cassano, MD, PhD</last_name>
    <phone>(617) 643-9622</phone>
    <email>pcassano@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Funes, MS</last_name>
    <email>cjfunes@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital at the Charlestown Navy Yard</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Cassano, MD, PhD</last_name>
      <phone>617-643-9622</phone>
      <email>pcassano@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christopher Funes, MS</last_name>
      <phone>617-643-2776</phone>
      <email>cjfunes@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Paolo Cassano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

